The global Interventional cardiology devices market is projected to grow from USD 31.12 billion in 2026 to USD 42.39 billion by 2031, at a CAGR of 6.4% during the forecast period. The market was valued at USD 29.41 billion in 2025.
Market growth is predominantly driven by the rising prevalence of cardiovascular diseases, including coronary artery disease and structural heart disorders, linked to population aging, sedentary lifestyles, and increasing rates of diabetes and obesity. The clinical shift from open-heart surgery toward minimally invasive, catheter-based interventions—offering shorter hospital stays, faster recovery, and lower complication rates—continues to accelerate device adoption.
Technological advancements in drug-eluting stents, transcatheter heart valves, intravascular ultrasound (IVUS), optical coherence tomography (OCT), and physiology-guided diagnostics are further supporting market expansion. Growing adoption of minimally invasive procedures, improvements in device design, and increasing investments in cardiovascular care infrastructure are expected to create continued opportunities for interventional cardiology device manufacturers through the forecast period.
Spotlights on the Industry’s Leading Interventional Cardiology Devices Companies
The interventional cardiology devices market is evolving rapidly, driven by advances in minimally invasive procedures, coronary intervention, structural heart therapies, intravascular imaging, and catheter-based technologies. In this dynamic environment, the following companies stand out for their technological capabilities, product portfolios, research investments, and contributions to cardiovascular interventions worldwide.
1. Boston Scientific Corporation
Boston Scientific Corporation is a major participant in the interventional cardiology devices market, offering a broad portfolio of technologies for coronary and structural heart interventions. Its solutions span stents, balloons, guidewires, catheters, and advanced procedural technologies. The company’s continued focus on minimally invasive cardiovascular interventions supports the growing adoption of catheter-based treatment approaches.
2. Medtronic
Medtronic maintains a strong presence in interventional cardiology through its portfolio of cardiovascular and structural heart technologies. The company develops solutions supporting coronary intervention, transcatheter procedures, and other minimally invasive cardiovascular treatments. Continued innovation in device design and procedural technologies contributes to the evolution of interventional cardiology.
3. Abbott
Abbott offers a broad range of interventional cardiology technologies covering coronary intervention, structural heart procedures, and intravascular imaging. Its portfolio includes stents, catheters, imaging systems, and other devices designed to support minimally invasive cardiovascular procedures. The company’s focus on advanced diagnostics and therapeutic technologies supports increasingly personalized intervention strategies.
4. Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a prominent participant in structural heart intervention, particularly transcatheter heart valve technologies. Its solutions support minimally invasive treatment for patients with structural heart conditions. The continued shift toward catheter-based valve replacement and repair is an important factor supporting demand for the company’s technologies.
5. Terumo Corporation
Terumo Corporation provides a broad portfolio of interventional cardiovascular devices, including catheters, guidewires, vascular access products, and coronary intervention technologies. Its solutions support minimally invasive procedures across cardiovascular care settings. The company’s focus on procedural efficiency and device innovation contributes to the continued development of catheter-based interventions.
6. B. Braun SE
B. Braun SE provides medical technologies supporting vascular access and interventional procedures. Its portfolio includes products designed to facilitate safe and efficient cardiovascular interventions. The company’s broad healthcare presence and focus on minimally invasive procedural technologies support its participation in the interventional cardiology ecosystem.
7. Koninklijke Philips N.V.
Koninklijke Philips N.V. plays an important role in interventional cardiology through advanced imaging, image-guided therapy, and cardiovascular procedure technologies. Its solutions help clinicians visualize anatomy and guide minimally invasive interventions. Integration of imaging, software, and procedural technologies is becoming increasingly important for complex cardiovascular procedures.
8. Integer Holdings Corporation
Integer Holdings Corporation develops components and technologies used in medical devices, including products supporting cardiovascular and interventional applications. Its expertise in engineering, materials, and device manufacturing enables the development of specialized components for minimally invasive medical technologies. The company supports the broader medical device ecosystem through its technology and manufacturing capabilities.
9. Teleflex Incorporated
Teleflex Incorporated provides a range of medical technologies used in vascular and interventional procedures. Its portfolio includes catheter-based and vascular access solutions designed to support minimally invasive interventions. The company’s emphasis on procedural technologies addresses the continuing demand for efficient and reliable cardiovascular intervention products.
10. Asahi Intecc Co., Ltd.
Asahi Intecc Co., Ltd. specializes in guidewires and catheter technologies used in complex cardiovascular interventions. Its products are designed to provide physicians with improved control and access during minimally invasive procedures. The company’s expertise in precision wire technology supports advanced coronary intervention and complex lesion treatment.
11. Cook
Cook provides medical devices and technologies supporting vascular and cardiovascular interventions. Its portfolio includes catheters, guidewires, vascular access products, and other minimally invasive solutions. The company’s focus on procedural technologies supports the increasing use of catheter-based approaches across cardiovascular care.
12. Cordis
Cordis is focused on interventional cardiovascular and endovascular technologies, offering products designed to support coronary and vascular procedures. Its portfolio includes catheters, guidewires, stents, and other intervention-focused devices. The company’s emphasis on physician-oriented solutions contributes to the development of minimally invasive cardiovascular care.
13. iVascular S.L.U.
iVascular S.L.U. develops technologies for interventional cardiology, with a focus on coronary intervention products and minimally invasive cardiovascular procedures. Its portfolio includes devices designed to support coronary treatment and vascular intervention. Continued innovation in device design contributes to expanding treatment options for patients undergoing catheter-based procedures.
14. Biosensors International Group, Ltd.
Biosensors International Group, Ltd. specializes in cardiovascular devices, particularly technologies for coronary intervention. Its portfolio includes drug-eluting stents and other products designed to support the treatment of coronary artery disease. The company’s focus on device development and minimally invasive cardiovascular procedures supports its role in the global interventional cardiology market.
15. Endocor GmbH
Endocor GmbH develops technologies for interventional cardiovascular applications, supporting minimally invasive approaches to the treatment of heart and vascular conditions. Its focus on specialized medical devices contributes to the development of catheter-based treatment options. Innovation in procedural technologies remains an important area of opportunity for the company.
16. InSitu Technologies Inc.
InSitu Technologies Inc. focuses on medical technologies designed for minimally invasive and interventional applications. Its solutions support the development of specialized cardiovascular procedures and device-based treatment approaches. The company’s focus on innovative technologies aligns with the broader transition toward catheter-based cardiovascular interventions.
17. Cardionovum GmbH
Cardionovum GmbH specializes in interventional cardiology technologies, with a focus on innovative solutions for coronary artery disease. Its product development efforts address the need for effective and minimally invasive treatment options. The company’s focus on coronary intervention contributes to the ongoing evolution of cardiovascular device technologies.
18. Medinol
Medinol develops cardiovascular devices and technologies for interventional applications, including coronary stent systems. The company focuses on innovative device designs intended to support minimally invasive treatment of cardiovascular conditions. Its engineering capabilities contribute to continued advancements in coronary intervention technologies.
19. Balton
Balton develops medical devices for cardiovascular and interventional applications, including products supporting coronary procedures. Its portfolio addresses the needs of healthcare professionals performing minimally invasive cardiovascular interventions. The company’s participation in the market reflects the expanding global demand for catheter-based cardiovascular technologies.
Conclusion:
The interventional cardiology devices market is undergoing continued transformation as healthcare providers increasingly adopt minimally invasive, catheter-based approaches for coronary and structural heart conditions. Rising cardiovascular disease prevalence, an aging population, and increasing rates of diabetes and obesity are supporting demand for advanced cardiovascular interventions.
The companies highlighted above represent key participants across coronary intervention, structural heart procedures, vascular access, intravascular imaging, and catheter-based technologies. Their continued investments in product development and interventional technologies are expected to influence the evolution of cardiovascular care worldwide.
